Phase 1 N=92 Interventions of Smoking Cessation During Pregnancy
Smoking Cessation
Primary: Participants' Smoking Status — 253.6; 678.9; 311.9; 479.6 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=145 A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications
Diagnostic Imaging
Primary: Creatinine Clearance — 1.1; 1.9 percent change
Phase 2 N=39 Effects of Vaporized Marijuana on Neuropathic Pain
Neuropathic Pain · Reflex Sympathetic Dystrophy · Peripheral Neuropathy
Primary: Participants With 30% or Greater Reduction in Pain Intensity — 61; 57; 26 percentage of participants
Phase 1 N=56 Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery
Hypoplastic Left Heart · Tetralogy of Fallot · Tricuspid Atresia
Primary: PK Profile of Dexmedetomidine — 28 mL/min/(kg^0.75)
Phase 3 N=1,152 LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
Psoriasis Vulgaris
Primary: Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4 — 64; 60; 5; 2 participants
N/A N=170 A Trial on Ultrasound-assisted Spinal Anaesthesia
Spinal Anaesthesia · Ultrasound
Primary: Success Rate of First-attempt of Spinal Anaesthesia — 54; 44 participants
N/A N=45 Alefacept in Patients With Severe Scalp Alopecia Areata
Alopecia Areata
Primary: The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values — 8.7; 13.6 percentage of…
Phase 3 N=23 Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)
Primary Immune Deficiency Disorder
Primary: Median of the Individual Subject's Rate of Adverse Events (AEs) Per Infusion — 0.167; 0.125; 0; 0 AEs per infusion
Phase 1 N=11 Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Breast Cancer
Primary: The Number of Participants Who Experienced Dose-limiting Adverse Events — 1; 0 participants
N/A N=32 Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Toxicities
Primary: Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL) — 2.70; 2.41; 2.70; 2.29 units on a scale
Phase 1 N=12 Ph1 Marinol Interaction Study - Part 2 - 1
Marijuana Dependence
Primary: Number of Participants That Experience Cardiovascular Effects of Smoked Marijuana or Has Any Other Combination Side Effects. — 6; 6 participants
Phase 1 N=50 Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide
Heart Failure
Primary: The Number of Participants Reporting Adverse Events (AEs) — 0; 0; 3; 0 Participants
Phase 3 N=143 Micronutrient Sprinkles in a Daycare Center
Diarrhea · Respiratory Infection
Primary: Proportion of Children of Diarrhea Episodes — 19.1; 14.7 percentage of participants
Phase 2 N=29 Memantine Treatment Study of Pathological Gambling
Pathological Gambling
Primary: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) — 21.8; 8.9 units on a scale
N/A N=232 Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)
Chronic Hepatitis C · Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 73 participants